This information is intended for healthcare professionals based in Ireland. If you are not a healthcare professional in Ireland, click here
This information is intended for healthcare professionals based in Ireland. If you are not a healthcare professional in Ireland, click here
These booklets may be read in its electronic form (PDF) or may be printed.
Please note: Switching from warfarin to ELIQUIS should only be done under close clinical supervision. Any prescribing decision should only be made by the prescribing healthcare professional based on sound clinical reasons and after appropriate assessment with patient involvement in the decision-making.
If a Patient Information Booklet is printed, please ensure that:
Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance at www.hpra.ie
Adverse reactions should also be reported to Bristol-Myers Squibb Medical Information on 1 800 749 749 or medical.information@bms.com